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their pain. Their pain intensity during last episode of painwas 5 on
a 10-point Numeric Rating Scale (NRS). 39% of the respondents
had moderate pain (NRS = 5–7), 43% had severe pain (NRS = 7),
67% had headaches, 22% had back pain. 96% of the acute pain
sufferers were using drugs for last three months. 96% of them
were taking Aspirin® (acetyl salicilic acid), 91% Vermidon®
(paracetamol), 90% Novalgin® (Dipyrone), and 80% Apranax®
(naproxen sodium). CONCLUSION: Six percent of Turkish
adults had acute pain. Sixty-seven percent of the respondents who
had acute pain had accompying disease causing the pain. Pain is a
major health care problem in Turkey that needs to be evaluated
and researched in depth.
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OBJECTIVES: There are two forms of injectable IV diclofenac
available (Dyloject bolus and Voltarol infusion). We conducted a
cost minimization analysis to determine the total cost of each
treatment strategy. METHODS: A decision-analytic model was
developed to estimate total treatment costs of IV bolus versus IV
infusion diclofenac. The modeled population was patients who
post-operatively would require injectable NSAIDs to control their
pain. The model timeframe was for the duration that a patient
required post-operative pain management with injectable medi-
cation. The model inputs included the actual/estimated cost of
medicines, the cost of the IV administration process (staff time and
consumables), and the cost of treating adverse events (staff time,
medicines and consumables). The unit costs and resources are
based on UK data. The results are expressed as Pounds Sterling
and as average cost per patient. One-way sensitivity analyses were
also conducted on key parameters. RESULTS: The total cost of
treating post-operative pain was less with IV bolus diclofenac
(Dyloject) than with IV infusion diclofenac (Voltarol). Diclofenac
IV bolus cost a mean27.84 per patient overall versus diclofenac
IV infusion mean cost of 78.61 per patient. The difference in
overall cost is attributable to the cost ofNSAIDs (IV bolus12.19
versus 1.69 IV Infusion), the cost of administering the NSAID
(IV bolus 9.72 versus 49.73 IV Infusion) and the cost of
consumables (IV bolus 1.40 versus 16.72 IV infusion). The
difference in the costs of rescuemedication (IV bolus2.48 versus
6.14 IV infusion) and of treating adverse events (IV bolus
2.061 versus 4.33 IV infusion) was less. One-way sensitivity
analyses show the results are sensitive to the cost of staff time and
consumables. CONCLUSION: Diclofenac IV bolus (Dyloject) is
cost saving relative to diclofenac IV infusion (Voltarol) in the
treatment of post-operative pain.
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OBJECTIVES: To develop an expected-cost model to examine
the impact of opioid rotation among patients with chronic non-
cancer pain from the payor perspective METHODS: A decision
tree was developed depicting pathways a patient may follow over
the course of 1 year while taking long acting opioids. Up to 2
switches and 5 dose adjustments were possible for each of the
three treatment arms: 1) MS Contin ER switch to OPANA ER; 2)
MS Contin ER switch to OxyContin ER; and 3) OPANA ER
switch to OxyContin ER for patients where morphine is not an
appropriate ﬁrst line treatment option. Cost data included drug
acquisition costs for extended release (ER) and immediate release
(IR) opioids, physician contact reimbursement for pain special-
ists and primary care physicians. Estimated rates for side effects
were assumed similar for the most frequently reported side effects
(constipation, nausea, somnolence and sedation) and were
applied to all treatment arms. RESULTS: A total of 149 possible
pathways of care were evaluated among the 3 treatment arms.
Assuming a BID regimen, expected-cost range for treatments 1,
2, and 3 were: $3426–$4299, $3829–$5073, and $4556–$5098,
respectively. IR cost contribution of the total expected-cost for
treatment arms 1, 2, and 3 amounted to 17%, 21% and 24%,
respectively, and was dependent on the total daily ER dose.
CONCLUSION: Opioid rotation is thought to be the result of
the need to switch opioids when a therapy is not well tolerated by
the patient. Having an effective alternative for rotation/switching
if ﬁrst line treatment fails has the potential to reduce incremental
down stream costs by decreasing physician contacts due to dose
adjustment or the need for further switching. Furthermore, the
lack of effective pain management combined with non-tolerated
side effects may also require the need for additional medications
for pain (IR) and side effects.
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OBJECTIVES: To analyze health and non-health resources utili-
zation and derived costs of treating treating refractory painful
Radiculopathy followed in PCS under routine medical practice.
METHODS: A 12-weeks cross-sectional and retrospective analy-
sis was carried out in year 2006 in a whole-nation representative
sample of PC centres. Men and women above 18 years, with
chronic pain (6-month or more) due to cervical (17%) or lumbar
(83%) radiculopathy, refractory to, at least, one previous anal-
gesic were included in the analysis. Health resources included
all-type medical visits, hospitalizations, complementary test and
pharmacological and non-pharmacological therapies. Non-
health included wages loses due to loss-work-days equivalents
(LWDE = absenteeism days + days working with reduced pro-
ductivity due to pain). Pain severity was measured by McGill-
pain scale. RESULTS: One-thousand-four-hundred-ﬁfty-two
subjects [55.8% women, 56.7 (12.5) years] with cervical or
lumbar radiculopathy were analyzed. Last-week mean pain
severity was 71.4 (15.1) mm with 61.4% declaring the pain as
severe or worst the day of collecting data. Previous mean (SD)
number of drugs was 2.6 (1.4), with a 24.0% on one-drug only;
81% on NSAIDs, 47% on paracetamol, 32% on opiods, 17% on
muscle-relaxants, 9% on antiepileptics, and 7% on antidepres-
sants. Quarterly mean LWDE was 41.1 (28.6) days. Medical
visits average per trimester was 9.1 (6.2), with 3.9% declaring
one-hospitalization. Quarterly total mean cost was €2970
(2114); €1032 (1207) direct health cost and €1938 (1490) indi-
rect cost. CONCLUSION: In the primary care setting, health and
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